The news: A gene-edited pig’s heart has been transplanted into a human being for the first time. David Bennett Sr., a man with terminal heart disease, received the genetically modified heart during an eight-hour operation on Friday January 7 at the University of Maryland Medical Center, which issued a statement last night. The operation was a last-ditch effort on behalf of Bennett, 57, who had been deemed ineligible for a conventional heart transplant. He had been in the hospital for more than six weeks before the procedure with life-threatening arrhythmia. “It was either die or do this transplant,” he said in the press statement. “I want to live. I know it’s a shot in the dark, but it’s my last choice.”
The technique: Ten genes in the donor pig were altered before the transplant could take place. Three of these genes cause human bodies to reject pig organs, so these were knocked out. Six genes were inserted to help control immune acceptance of the pig heart, and one additional gene was knocked out to stop excessive growth of the pig heart tissue.
The Maryland team also used an experimental drug to suppress the immune system and prevent rejection, and a new machine that pushed fluid through the tissue to make sure the pig’s heart remained viable until the procedure. The FDA gave emergency go-ahead for the procedure on New Year’s Eve, according to the New York Times.
What’s next: The demand for organs is vast, with nearly 107,000 people on the US transplant waiting list; 17 of them die every day, according to the Health Resources and Services Administration, a federal agency.
Early results look promising for Bennett, who is expected to come off the heart-lung bypass machine he’d been relying on to keep him alive today (January 11). He will be very closely monitored over the coming days and weeks for any signs of rejection or infection.
New frontier: While xenotransplantation, the process of transplanting animal organs or tissues into humans, has a long and often unsuccessful history, new gene-editing technologies are making it more viable. The gene-edited pig in last week’s operation was supplied by Revivicor, one of several biotech companies working to develop pig organs to transplant into humans.
Revivicor was also behind a successful transplantation of a pig’s kidney into a human patient last October, which was a major milestone in proving the viability of its techniques. As well as Revivicor, Harvard scientist George Church cofounded a company, eGensisis, that is working on using CRISPR gene editing to make animal organs viable for human transplant, although his ambitious proposed time scale has fallen off track.
Correction: We updated the first line to make it clear this was the first gene-edited heart.
Biotechnology and health
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
A biotech company says it put dopamine-making cells into people’s brains
The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.
Tiny faux organs could crack the mystery of menstruation
Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.
After 25 years of hype, embryonic stem cells are still waiting for their moment
Research roadblocks and political debates have delayed progress—but scientists are inching closer to delivering a cure.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.